Filing Details

Accession Number:
0001209191-14-021638
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-18 19:23:48
Reporting Period:
2014-03-14
Filing Date:
2014-03-18
Accepted Time:
2014-03-18 19:23:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949858 Oncogenex Pharmaceuticals Inc. OGXI In Vitro & In Vivo Diagnostic Substances (2835) 954343413
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1568605 D. Susan Wyrick 1522 217Th Place Se
Suite 100
Bothell WA 98021
Pao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-14 516 $0.00 1,494 No 4 M Direct
Common Stock Disposition 2014-03-17 182 $12.25 1,312 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit (RSU) Disposition 2014-03-14 516 $0.00 516 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2014-03-14 10,000 $0.00 10,000 $11.79
Common Stock Restricted Stock Unit (RSU) Acquisiton 2014-03-14 5,000 $0.00 5,000 $0.00
Common Stock Restricted Stock Unit (RSU) Acquisiton 2014-03-14 10,000 $0.00 10,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,547 2017-01-31 No 4 M Direct
10,000 2024-03-14 No 4 A Direct
5,000 2018-04-13 No 4 A Direct
10,000 2016-03-31 No 4 A Direct
Footnotes
  1. Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
  2. Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
  3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
  4. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
  5. The options vest in monthly installments over 48 months commencing one month from January 1, 2014.
  6. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
  7. Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) the achievement of certain milestones for certain clinical trials, and (ii) the first trading day thereafter on which the issuer's trading window is open, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones.